Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

EClinicalMedicine

Topics

Medicine

Pathology

Dermatology

Cell Biology

Nutrition And Dietetics

Show all topics

DOI

10.1016/j.eclinm.2024.102655

License

CC-BY-NC-ND